Literature DB >> 12738163

The evaluation and management of hirsutism.

Ricardo Azziz1.   

Abstract

Hirsutism is the presence of terminal (coarse) hairs in females in a male-like pattern, affecting between 5% and 15% of women, depending on definition. Hirsutism has a significant negative impact on psychosocial development and is usually a sign of an underlying endocrine abnormality-namely, androgen excess. The most common cause of androgen excess is the polycystic ovary syndrome (PCOS), with 21-hydroxylase-deficient nonclassic adrenal hyperplasia, the hyperandrogenic insulin-resistant acanthosis nigricans syndrome, androgen-secreting tumors, and androgenic drug intake occurring less frequently. However, although 70-80% of patients with androgen excess demonstrate hirsutism, this sign may be less prevalent among women of Asian extraction. Conversely, not all hirsute patients have evidence of detectable androgen excess, as 5-15% of these women have "idiopathic hirsutism," with normal ovulatory function and androgen levels. There is a strong familial predilection for hirsutism, primarily because the underlying endocrine disorders (eg, PCOS) and the factors regulating the development of hair growth (eg, androgen receptor activity, 5alpha-reductase activity) have a strong genetic component. The diagnostic evaluation of the potentially hirsute patient first involves confirming the presence of hirsutism and then excluding associated or etiological abnormalities and disorders (eg, ovulatory dysfunction, adrenal hyperplasia, diabetes, thyroid hormone abnormalities). Treatment should be undertaken using combination therapy, to possibly include 1) hormonal suppression (oral contraceptives, long-acting gonadotropin-releasing hormone analogues, and insulin sensitizers), 2) peripheral androgen blockade (spironolactone, flutamide, cyproterone acetate, or finasteride), and 3) mechanical/cosmetic amelioration and destruction of the unwanted hairs (electrology and, potentially, laser hair removal). The application of eflornithine hydrochloride 13.9% topical cream may also be useful to ameliorate unwanted facial hair growth. Overall, although hirsutism is a frequent and distressing abnormality often signaling an underlying endocrine disorder, a systematic approach to evaluation will uncover the etiology, and combination therapy will provide satisfactory treatment for most patients.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12738163     DOI: 10.1016/s0029-7844(02)02725-4

Source DB:  PubMed          Journal:  Obstet Gynecol        ISSN: 0029-7844            Impact factor:   7.661


  24 in total

1.  Interventional studies for polycystic ovarian syndrome in children and adolescents.

Authors:  Patricia Myriam Vuguin
Journal:  Ped Health       Date:  2010-02

2.  A method to improve the efficacy of topical eflornithine hydrochloride cream.

Authors:  Amit Kumar; Youssef W Naguib; Yan-Chun Shi; Zhengrong Cui
Journal:  Drug Deliv       Date:  2014-09-03       Impact factor: 6.419

3.  Altering hirsutism through ovulation induction in women with polycystic ovary syndrome.

Authors:  Lauren W Roth; Hao Huang; Richard S Legro; Michael P Diamond; Christos Coutifaris; Sandra A Carson; Michael P Steinkampf; Bruce R Carr; Peter G McGovern; Nicholas A Cataldo; Gabriella G Gosman; John E Nestler; Evan R Myers; Heping Zhang; William D Schlaff
Journal:  Obstet Gynecol       Date:  2012-06       Impact factor: 7.661

4.  Metabolic Effects of a Commonly Used Combined Hormonal Oral Contraceptive in Women With and Without Polycystic Ovary Syndrome.

Authors:  Adeola A Adeniji; Paulina A Essah; John E Nestler; Kai I Cheang
Journal:  J Womens Health (Larchmt)       Date:  2016-02-12       Impact factor: 2.681

Review 5.  Polycystic ovarian syndrome: diagnosis and management.

Authors:  Michael T Sheehan
Journal:  Clin Med Res       Date:  2004-02

Review 6.  Polycystic ovary syndrome: etiology, pathogenesis and diagnosis.

Authors:  Mark O Goodarzi; Daniel A Dumesic; Gregorio Chazenbalk; Ricardo Azziz
Journal:  Nat Rev Endocrinol       Date:  2011-01-25       Impact factor: 43.330

7.  Sonographic markers of ovarian morphology, but not hirsutism indices, predict serum total testosterone in women with regular menstrual cycles.

Authors:  Heidi Vanden Brink; Amy D Willis; Brittany Y Jarrett; Annie W Lin; Steven Soler; Siân Best; Erica L Bender; Andrew K Peppin; Kathleen M Hoeger; Marla E Lujan
Journal:  Fertil Steril       Date:  2016-01-27       Impact factor: 7.329

8.  The changing role of the clinical laboratory in the investigation of polycystic ovarian syndrome.

Authors:  A Michael Wallace; Naveed Sattar
Journal:  Clin Biochem Rev       Date:  2007-08

9.  A population-based study of the relationship between idiopathic hirsutism and metabolic disturbances.

Authors:  F Ramezani Tehrani; S Behboudi-Gandevani; M Simbar; F Azizi
Journal:  J Endocrinol Invest       Date:  2014-09-09       Impact factor: 4.256

10.  A comparison between finasteride, flutamide, and finasteride plus flutamide combination in the treatment of hirsutism.

Authors:  K Unluhizarci; D Ozel; F Tanriverdi; Z Karaca; F Kelestimur
Journal:  J Endocrinol Invest       Date:  2009-01       Impact factor: 4.256

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.